S&P 500   3,974.64 (+1.88%)
DOW   31,916.47 (+2.09%)
QQQ   292.50 (+1.32%)
AAPL   142.57 (+3.62%)
MSFT   259.91 (+2.91%)
FB   194.50 (+0.50%)
GOOGL   2,228.67 (+2.32%)
AMZN   2,145.31 (-0.30%)
TSLA   673.31 (+1.42%)
NVDA   167.74 (+0.48%)
BABA   86.51 (-0.32%)
NIO   15.78 (-4.01%)
AMD   94.68 (+1.26%)
CGC   5.18 (-6.16%)
MU   69.33 (+0.62%)
T   20.87 (+2.30%)
GE   75.96 (+0.94%)
F   12.84 (+2.72%)
DIS   105.11 (+2.63%)
AMC   11.67 (-2.99%)
PFE   53.11 (+1.22%)
PYPL   81.04 (+0.62%)
NFLX   185.30 (-0.56%)
S&P 500   3,974.64 (+1.88%)
DOW   31,916.47 (+2.09%)
QQQ   292.50 (+1.32%)
AAPL   142.57 (+3.62%)
MSFT   259.91 (+2.91%)
FB   194.50 (+0.50%)
GOOGL   2,228.67 (+2.32%)
AMZN   2,145.31 (-0.30%)
TSLA   673.31 (+1.42%)
NVDA   167.74 (+0.48%)
BABA   86.51 (-0.32%)
NIO   15.78 (-4.01%)
AMD   94.68 (+1.26%)
CGC   5.18 (-6.16%)
MU   69.33 (+0.62%)
T   20.87 (+2.30%)
GE   75.96 (+0.94%)
F   12.84 (+2.72%)
DIS   105.11 (+2.63%)
AMC   11.67 (-2.99%)
PFE   53.11 (+1.22%)
PYPL   81.04 (+0.62%)
NFLX   185.30 (-0.56%)
S&P 500   3,974.64 (+1.88%)
DOW   31,916.47 (+2.09%)
QQQ   292.50 (+1.32%)
AAPL   142.57 (+3.62%)
MSFT   259.91 (+2.91%)
FB   194.50 (+0.50%)
GOOGL   2,228.67 (+2.32%)
AMZN   2,145.31 (-0.30%)
TSLA   673.31 (+1.42%)
NVDA   167.74 (+0.48%)
BABA   86.51 (-0.32%)
NIO   15.78 (-4.01%)
AMD   94.68 (+1.26%)
CGC   5.18 (-6.16%)
MU   69.33 (+0.62%)
T   20.87 (+2.30%)
GE   75.96 (+0.94%)
F   12.84 (+2.72%)
DIS   105.11 (+2.63%)
AMC   11.67 (-2.99%)
PFE   53.11 (+1.22%)
PYPL   81.04 (+0.62%)
NFLX   185.30 (-0.56%)
S&P 500   3,974.64 (+1.88%)
DOW   31,916.47 (+2.09%)
QQQ   292.50 (+1.32%)
AAPL   142.57 (+3.62%)
MSFT   259.91 (+2.91%)
FB   194.50 (+0.50%)
GOOGL   2,228.67 (+2.32%)
AMZN   2,145.31 (-0.30%)
TSLA   673.31 (+1.42%)
NVDA   167.74 (+0.48%)
BABA   86.51 (-0.32%)
NIO   15.78 (-4.01%)
AMD   94.68 (+1.26%)
CGC   5.18 (-6.16%)
MU   69.33 (+0.62%)
T   20.87 (+2.30%)
GE   75.96 (+0.94%)
F   12.84 (+2.72%)
DIS   105.11 (+2.63%)
AMC   11.67 (-2.99%)
PFE   53.11 (+1.22%)
PYPL   81.04 (+0.62%)
NFLX   185.30 (-0.56%)
NASDAQ:AVDL

Avadel Pharmaceuticals Earnings Date, Estimates, & History

$3.76
-0.08 (-2.08%)
(As of 05/23/2022 02:04 PM ET)
Add
Compare
Today's Range
$3.67
$3.85
50-Day Range
$3.55
$7.36
52-Week Range
$3.49
$11.59
Volume
8,482 shs
Average Volume
551,116 shs
Market Capitalization
$221.96 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.13

Earnings Summary

Upcoming
Earnings Date
Aug. 8Estimated
Actual EPS
(May. 9)
-$0.45 Missed By -$0.02
Consensus EPS
(May. 9)
-$0.43
Skip Charts & View Estimated and Actual Earnings Data

Avadel Pharmaceuticals Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

Avadel Pharmaceuticals Estimated Revenue and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Avadel Pharmaceuticals (NASDAQ:AVDL) Earnings Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateCompany Guidance
Q1 20224($0.47)($0.41)($0.45) 
Q2 20224($0.49)($0.39)($0.45) 
Q3 20224($0.80)($0.40)($0.51) 
Q4 20223($0.44)($0.24)($0.33) 
FY 202215($2.20)($1.44)($1.73) 
Q1 20231($0.26)($0.26)($0.26) 
Q2 20231($0.18)($0.18)($0.18) 
Q3 20231($0.11)($0.11)($0.11) 

AVDL Earnings Information

Avadel Pharmaceuticals last posted its quarterly earnings data on May 9th, 2022. The reported ($0.45) EPS for the quarter, missing the consensus estimate of ($0.43) by $0.02. Avadel Pharmaceuticals has generated ($1.54) earnings per share over the last year (($1.54) diluted earnings per share). Earnings for Avadel Pharmaceuticals are expected to grow in the coming year, from ($1.60) to ($0.19) per share. Avadel Pharmaceuticals has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Monday, August 8th, 2022 based off prior year's report dates.

Avadel Pharmaceuticals (NASDAQ:AVDL) Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueActions
8/8/2022
(Estimated)
        
5/9/20223/31/2022($0.43)($0.45)($0.02)    
3/17/2022Q4 2021($0.41)($0.38)+$0.03($0.38)    
11/8/20219/30/2021($0.38)($0.38)($0.38)    
8/8/20216/30/2021($0.31)($0.33)($0.02)($0.33)      
5/9/20213/31/2021($0.32)($0.23)+$0.09($0.23)    
3/8/2021Q4($0.28)($0.19)+$0.09($0.29)  
11/14/20209/30/2020($0.25)($0.20)+$0.05($0.20)    
8/10/2020Q2 2020($0.18)($0.16)+$0.02($0.81)$8.08 million$10.09 million
5/11/20203/31/2020($0.27)($0.02)+$0.25($0.02)$10.25 million$12.24 million  
3/12/2020Q4($0.25)($0.07)+$0.18($0.07)$11.00 million$11.00 million    
11/12/20199/30/2019($0.27)($0.24)+$0.03($0.24)$14.23 million    
8/9/2019Q2 2019($0.23)($0.23)($0.23)$17.55 million  
5/8/20193/31/2019($0.40)($0.35)+$0.05($0.35)$16.44 million  
3/15/201912/31/2018($0.52)($0.46)+$0.06$0.80$20.92 million    
11/5/20189/30/2018($0.53)($0.43)+$0.10($0.87)$20.11 million$19.83 million    
8/7/20186/30/2018($0.37)($0.09)+$0.28($1.01)$25.02 million$29.23 million  
5/2/20183/31/2018($0.24)($0.32)($0.08)($0.36)$29.60 million$33.29 million  
3/8/2018Before Market($0.23)($0.28)($0.05)($0.32)$34.16 million$34.20 million  
11/8/2017Q3($0.04)$0.09+$0.13($0.34)$38.22 million$39.68 million
8/8/20176/30/2017$0.05$0.19+$0.14($0.30)$45.17 million$46.30 million  
5/9/20173/31/2017$0.07$0.26+$0.19($0.07)$46.01 million$52.50 million  
3/7/201712/31/2016($0.03)$0.26+$0.29($0.11)$34.72 million$43.09 million  
11/7/2016Q316($0.07)($0.08)($0.01)$0.38$30.70 million$32.10 million  
8/8/2016Q216$0.06($0.02)($0.08)$0.44$32.80 million$38.90 million
5/9/2016Q116$0.14$0.04($0.10)$0.23$34.00 million$36.20 million
3/10/2016Q415$0.09$0.32+$0.23($1.11)$44.69 million$43.40 million  
11/12/2015Q215$0.23$0.28+$0.05$0.81$50.33 million$47.30 million  
7/30/2015Q2$0.40$0.34($0.06)$1.11$62.50 million$49.80 million  
5/15/2015Q115$0.18$0.34+$0.16$0.41$37.37 million$32.73 million  
3/19/2015Q414($0.22)($0.12)+$0.10$0.45$13.10 million$3.00 million
10/31/2014Q3 14($0.12)($0.16)($0.04)($0.06)$12.00 million$7.00 million  
7/29/2014Q214($0.08)($0.13)($0.05)$0.29$9.92 million$8.10 million
5/12/2014Q1 14($0.15)($0.15)$0.64$7.47 million$9.20 million  
3/11/2014Q4 2013($0.26)$0.20+$0.46$0.20$5.74 million$6.18 million
10/31/2013Q3 2013($0.22)($0.22)($0.19)$6.47 million$5.60 million  
7/29/2013Q2 2013($0.09)($0.09)$1.11$5.35 million$5.50 million
5/7/2013Q1 2013($0.33)($0.23)+$0.10($0.11)$6.11 million$5.10 million
2/28/2013Q4 2012($0.19)($0.14)+$0.05($0.64)
11/5/2012Q312($0.19)($0.26)($0.07)$6.35 million$5.40 million
7/25/2012Q2 2012($0.08)($0.25)($0.17)($0.45)
5/7/2012Q1 2012($0.07)($0.19)($0.12)($0.19)
3/14/2012Q4 2011$0.10($0.08)($0.18)($0.08)
11/2/2011Q3 2011($0.09)$0.07+$0.16$0.07
7/25/2011Q2 2011($0.09)($0.14)($0.05)($0.14)
5/9/2011Q1 2011($0.11)($0.20)($0.09)($0.20)
3/3/2011Q4 2010$0.05$0.11+$0.06$0.11
11/4/2010Q3 2010($0.14)($0.14)($0.14)
7/28/2010Q2 2010($0.05)($0.18)($0.13)($0.18)
5/5/2010Q1 2010($0.13)($0.17)($0.04)($0.17)
3/8/2010Q4 2009($0.10)($0.24)($0.14)($0.24)
11/16/2009Q3 2009($0.09)($0.14)($0.05)($0.14)
8/5/2009Q2 2009($0.10)($0.15)($0.05)($0.15)
5/11/2009Q1 2009($0.14)$0.05+$0.19$0.05
3/4/2009Q4 2008($0.02)($0.11)($0.09)($0.11)
11/3/2008Q3 2008($0.17)($0.10)+$0.07($0.10)
8/6/2008Q2 2008($0.25)($0.14)+$0.11($0.14)
5/13/2008Q1 2008($0.15)($0.15)($0.15)
3/3/2008Q4 2007($0.30)($0.23)+$0.07($0.23)
(Earnings results data provided by Zacks Investment Research)












Avadel Pharmaceuticals (NASDAQ:AVDL) Earnings Frequently Asked Questions

When is Avadel Pharmaceuticals's earnings date?

Avadel Pharmaceuticals has not confirmed its next earnings publication date, but the company's estimated earnings date is Monday, August 8th, 2022 based off last year's report dates. Learn more on AVDL's earnings history.

Did Avadel Pharmaceuticals beat their earnings estimates last quarter?

In the previous quarter, Avadel Pharmaceuticals (NASDAQ:AVDL) missed the analysts' consensus estimate of ($0.43) by $0.02 with a reported earnings per share (EPS) of ($0.45). Learn more on analysts' earnings estimate vs. AVDL's actual earnings.

How can I listen to Avadel Pharmaceuticals's earnings conference call?

The conference call for Avadel Pharmaceuticals's latest earnings report can be listened to online. Listen to Conference Call

How can I read Avadel Pharmaceuticals's conference call transcript?

The conference call transcript for Avadel Pharmaceuticals's latest earnings report can be read online. Read Transcript

How much revenue does Avadel Pharmaceuticals generate each year?

Avadel Pharmaceuticals (NASDAQ:AVDL) has a recorded annual revenue of $22.33 million.

How much profit does Avadel Pharmaceuticals generate each year?

Avadel Pharmaceuticals (NASDAQ:AVDL) has a recorded net income of -$77.33 million. AVDL has generated -$1.54 earnings per share over the last four quarters.

What is Avadel Pharmaceuticals's EPS forecast for next year?

Avadel Pharmaceuticals's earnings are expected to grow from ($1.60) per share to ($0.19) per share in the next year.

This page was last updated on 5/23/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.